Business Description
Orexo AB
ISIN : US68616W1027
Share Class Description:
ORXOY: ADRTotal Employee Number:
65Compare
Compare
Traded in other countries / regions
ORX.SwedenORXOF.USA0H19.UKC5G.Germany IPO Date
2013-08-28Description
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 55.17 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.05 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.78 | |||||
Beneish M-Score | 1.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -66.9 | |||||
3-Year EBITDA Growth Rate | -49.7 | |||||
3-Year EPS without NRI Growth Rate | -31.1 | |||||
3-Year FCF Growth Rate | 2 | |||||
3-Year Book Growth Rate | 35.8 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 75.58 | |||||
9-Day RSI | 60.01 | |||||
14-Day RSI | 48.87 | |||||
3-1 Month Momentum % | -22.83 | |||||
6-1 Month Momentum % | -21.35 | |||||
12-1 Month Momentum % | 38.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.03 | |||||
Quick Ratio | 2.03 | |||||
Cash Ratio | 1.64 | |||||
Days Inventory | 887.84 | |||||
Days Sales Outstanding | 205.33 | |||||
Days Payable | 1293.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | 16.02 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 92.46 | |||||
Operating Margin % | -90.09 | |||||
Net Margin % | 212.6 | |||||
EBITDA Margin % | -63.79 | |||||
FCF Margin % | -28.13 | |||||
OCF Margin % | -28.09 | |||||
ROE % | 955.81 | |||||
ROA % | 74.6 | |||||
ROIC % | -64 | |||||
3-Year ROIIC % | 40.97 | |||||
ROC (Joel Greenblatt) % | -310.62 | |||||
ROCE % | -49.49 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 1.32 | |||||
PS Ratio | 3.95 | |||||
PB Ratio | 2.36 | |||||
Price-to-Tangible-Book | 2.35 | |||||
EV-to-EBIT | -2.18 | |||||
EV-to-Forward-EBIT | 61.06 | |||||
EV-to-EBITDA | -3.08 | |||||
EV-to-Forward-EBITDA | 9.6 | |||||
EV-to-Revenue | 1.96 | |||||
EV-to-Forward-Revenue | 1.3 | |||||
EV-to-FCF | -7.08 | |||||
Price-to-GF-Value | 3.77 | |||||
Price-to-Median-PS-Value | 1.92 | |||||
| Price-to-Net-Current-Asset-Value | 3.7 | |||||
| Price-to-Net-Cash | 6.06 | |||||
Earnings Yield (Greenblatt) % | -45.87 | |||||
FCF Yield % | -7.9 |
Orexo AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Orexo AB Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-22 07:00 | In 116 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-22 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-07-16 07:00 | In 18 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-16 | In 17 days | ||
| General meeting for 2026 | 2026-05-07 16:00 | 2.05 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-28 14:00 | 2.65 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 2.65 (+0.00%) | ||
| Annual report for 2025 | 2026-03-27 | 2.65 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-05 14:00 | 2.60 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-05 07:00 | 2.60 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:ORXOY
No articles.
Press Release
Articles on Orexo AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers